2,966 reports of this reaction
3.0% of all VENETOCLAX reports
#4 most reported adverse reaction
FEBRILE NEUTROPENIA is the #4 most commonly reported adverse reaction for VENETOCLAX, manufactured by AbbVie Inc.. There are 2,966 FDA adverse event reports linking VENETOCLAX to FEBRILE NEUTROPENIA. This represents approximately 3.0% of all 98,823 adverse event reports for this drug.
VENETOCLAX has an overall safety score of 88 out of 100. Patients taking VENETOCLAX who experience febrile neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FEBRILE NEUTROPENIA is a less commonly reported adverse event for VENETOCLAX, but still significant enough to appear in the safety profile.
In addition to febrile neutropenia, the following adverse reactions have been reported for VENETOCLAX:
The following drugs have also been linked to febrile neutropenia in FDA adverse event reports:
FEBRILE NEUTROPENIA has been reported as an adverse event in 2,966 FDA reports for VENETOCLAX. This does not prove causation, but indicates an association observed in post-market surveillance data.
FEBRILE NEUTROPENIA accounts for approximately 3.0% of all adverse event reports for VENETOCLAX, making it a notable side effect.
If you experience febrile neutropenia while taking VENETOCLAX, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.